OBJECTIVE: To estimate the magnitude of over-diagnosis and of potential and actual over-treatment regarding prostate cancer, taking comorbidities into account. MATERIALS AND METHODS: We used a sample collected by the French cancer registries of 1840 cases (T1: 583; T2: 1257) diagnosed in 2001. The proportion of over-diagnosed and over-treated patients was estimated by comparing life expectancy (LE), including or not comorbidities, with natural LE with cancer, using several assumptions from the literature. We distinguished potential and actual over-treatment according to the treatment that patients actually received. RESULTS: Among patients with T1 tumors the proportion of potential over-treatment using LE adjusted for comorbidity varied from 29.5% to 53.5%, using LE adjusted on comorbidities, and varied from 9.3% to 22.2% regarding actual over-treatment. Between 7.7% and 24.4% of patient's receiving a radical prostatectomy, and between 30.8% and 62.5% of those receiving radiotherapy, were over-treated. Among patients with T2 tumors, the proportions of potential and actual over-treatment were 0.9% and 2.0%. Two per cent of patients receiving a radical prostatectomy and 4.9% of those receiving radiotherapy were over-treated. Comorbidities dramatically increased these proportions to nearly 100% of patients, with more than two comorbidities being potentially over-treated and around 33% actually over-treated. CONCLUSIONS: According to the French incidence, 3200-4800 French patients may be over-treated, among whom a large proportion of patients had comorbidities. The real issue is to offer the most appropriate treatment to people with low-grade tumors and comorbidities.
OBJECTIVE: To estimate the magnitude of over-diagnosis and of potential and actual over-treatment regarding prostate cancer, taking comorbidities into account. MATERIALS AND METHODS: We used a sample collected by the French cancer registries of 1840 cases (T1: 583; T2: 1257) diagnosed in 2001. The proportion of over-diagnosed and over-treated patients was estimated by comparing life expectancy (LE), including or not comorbidities, with natural LE with cancer, using several assumptions from the literature. We distinguished potential and actual over-treatment according to the treatment that patients actually received. RESULTS: Among patients with T1 tumors the proportion of potential over-treatment using LE adjusted for comorbidity varied from 29.5% to 53.5%, using LE adjusted on comorbidities, and varied from 9.3% to 22.2% regarding actual over-treatment. Between 7.7% and 24.4% of patient's receiving a radical prostatectomy, and between 30.8% and 62.5% of those receiving radiotherapy, were over-treated. Among patients with T2 tumors, the proportions of potential and actual over-treatment were 0.9% and 2.0%. Two per cent of patients receiving a radical prostatectomy and 4.9% of those receiving radiotherapy were over-treated. Comorbidities dramatically increased these proportions to nearly 100% of patients, with more than two comorbidities being potentially over-treated and around 33% actually over-treated. CONCLUSIONS: According to the French incidence, 3200-4800 French patients may be over-treated, among whom a large proportion of patients had comorbidities. The real issue is to offer the most appropriate treatment to people with low-grade tumors and comorbidities.
Authors: Jennifer L Lund; Tzy-Mey Kuo; M Alan Brookhart; Anne-Marie Meyer; Alexandra F Dalton; Christine E Kistler; Stephanie B Wheeler; Carmen L Lewis Journal: Pharmacoepidemiol Drug Saf Date: 2019-03-19 Impact factor: 2.890
Authors: Piwen Wang; Tien Phan; David Gordon; Seyung Chung; Susanne M Henning; Jaydutt V Vadgama Journal: Mol Nutr Food Res Date: 2014-12-05 Impact factor: 5.914
Authors: Xiaoyu Wang; Catherine S Grasso; Kristina M Jordahl; Suzanne Kolb; Yaw A Nyame; Jonathan L Wright; Elaine A Ostrander; Dean A Troyer; Raymond Lance; Ziding Feng; James Y Dai; Janet L Stanford Journal: Prostate Cancer Prostatic Dis Date: 2020-02-18 Impact factor: 5.554
Authors: Pierre Lunardi; Guillaume Ploussard; Pascale Grosclaude; Mathieu Roumiguié; Michel Soulié; Jean Baptiste Beauval; Bernard Malavaud Journal: World J Urol Date: 2016-07-21 Impact factor: 4.226
Authors: Philippe Tuppin; Solène Samson; Anne Fagot-Campagna; Bertrand Lukacs; François Alla; Fred Paccaud; Jean-Christophe Thalabard; Eric Vicaut; Michel Vidaud; Bertrand Millat Journal: BMC Urol Date: 2014-06-13 Impact factor: 2.264